Bank of America (BofA) recently released the findings of an employer survey that found that the pharmacy benefit marketplace is highly competitive, confirmed that surveyed employers believe their pharmacy benefit company is transparent to them, and underscored the savings, flexibility,
(Washington, D.C.) — Today, representative organizations of America’s pharmaceutical supply and payment chain, including prescription and over-the-counter brand and generic manufacturers; wholesalers; retail, specialty, and managed care, pharmacies; health insurance providers and other payers; pharmacists in hospitals and health systems; and
Bass Explains Opposition to Legislation, Risk of Drug Companies Lowering Rx Discounts On Wednesday, expert witnesses testifying before the U.S. House Committee on Energy & Commerce Subcommittee on Health highlighted the critical value pharmacy benefit companies provide for patients, employers, and
PBMs: Committed to Helping Patients The Critical Path Forward: Rx Policies to Reduce Patient Costs, Improve Access For America’s pharmacy benefit managers, PBMs, our core mission is to increase access to affordable prescription drugs for all Americans. But more can
Speakers Discuss Pharmacy Benefit Company Innovations, Importance of Protecting Cost Saving Role, and Solutions to Improve Affordability
In case you missed it, JC Scott, president and CEO of the Pharmaceutical Care Management Association (PCMA), discusses the root cause of high drug prices – big drug companies’ anti-competitive tactics used to keep more affordable prescription drugs from entering
The Medicare Prescription Drug Rebate Rule PCMA Urges Congress to Permanently Repeal Rebate Rule This Year The Medicare Part D prescription drug benefit provides our nation’s seniors with affordable drug coverage, which is more important now than ever. The rebate
A recent blog (“Payers and PBMs Profit from Obscure Pharmacy Fees, While Seniors See No Relief in Prescription Costs”) suggests performance-based price concessions are retained by PBMs, restrict the growth of independent pharmacies, and inflate Medicare Part D enrollee’s out-of-pocket costs—unfounded
Unlocking an Affordable Future Unlocking an Affordable Future NEWSROOM PCMA Releases Statement on CMS Part D Biosimilar Substitution Announcement NEWSROOM PCMA Releases Statement on CMS Part D Biosimilar Substitution Announcement Stop The Billion-Dollar Big Pharma Bailout Before It’s Too Late
©2024 PCMA. All Rights Reserved.
